Schizophrenia

Role for raloxifene in postmenopausal women with schizophrenia

24/02/2010 | The selective oestrogen receptor modulator raloxifene may have a role in treating postmenopausal women with schizophrenia, a small pooled analysis finds.


Antipsychotic given green light for teens

04/02/2010 | The Australian Drug Evaluation Committee has backed an application for an antipsychotic drug to be approved for use in children with schizophrenia.


Fish oil reduces psychosis in high-risk adolescents

04/02/2010 | Fish oil may protect young people at risk of schizophrenia from developing psychosis, Australian researchers have found.


Exercise could be beneficial in schizophrenia

03/02/2010 | Aerobic exercise increases hippocampal volume in patients with and without schizophrenia, but further studies are needed to determine its effectiveness as a long term treatment option in schizophrenic patients, a randomised study concludes.


Atypical deltoid injection on PBS

03/02/2010 | The first atypical deltoid injection for schizophrenia and related psychoses has been added to the Pharmaceutical Benefits Scheme.


Evidence inconclusive for sulpiride augmentation

19/01/2010 | Sulpiride plus clozapine is likely to be more effective than clozapine alone to treat patients with treatment-resistant schizophrenia, but evidence is weak and more research is needed, a Cochrane review concludes.


Long-acting olanzapine pamoate listed on PBS

03/12/2009 | Long-acting olanzapine pamoate was listed on the Pharmaceutical Benefits Scheme this week for the treatment of adult patients with schizophrenia who have been stabilised with oral olanzapine.


Community treatment orders double

12/11/2009 | The number of community treatment orders doubled between 1998 and 2002, and most people subject to an order were prescribed antipsychotic long-acting injections, an Australian study finds.


Nurses curb antipsychotic weight gain

04/11/2009 | Researchers from Melbourne have come up with a practical solution to address existing barriers in implementing cardiometabolic monitoring in patients prescribed antipsychotics.


Suicide risk of first-episode psychosis examined

04/11/2009 | The risk of suicide after first-episode psychosis remains high for at least seven years after starting treatment, and previous self-harm is the key predictor of a future suicide event, Australian research finds.


More Schizophrenia news

Journals

Members of Psychiatry Update can access the following journals for free:

Most viewed articles this week

Recent comments

Related sites